Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.
Chordia Therapeutics Inc is among a number of new Japanese bioventures born out of former research activities at Takeda Pharmaceutical Co. Ltd., but is now looking to blaze its own trail as it progresses a number of novel oncology assets.
The Fujisawa-based operation was formed in November 2017 around a portfolio of selected assets that originally came out of the...
Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.
With financial help from the founder of Uniqlo, Japan’s leading facility for induced pluripotent stem cells is aiming to automate production to slash costs and kick-start R&D in the field.
The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get those submissions in by this date. Sponsorship opportunities and tables for the event are also available.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
